Mesothelioma

PrE0506 / DREAM3R



DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

STATUS: Active


Patients with malignant pleural mesothelioma (MPM) that cannot be surgically removed will receive first-line treatment with standard chemotherapy of cisplatin or carboplatin and pemetrexed. Two-thirds of the participants in the study will be randomly assigned to also receive a new treatment called durvalumab. Durvalumab is an antibody (a type of human protein) that works by blocking a body substance called Programmed Death-Ligand 1 (PD-L1). Blocking PD-L1 helps the body's immune system attack cancer cells. Research has shown that durvalumab can slow tumor growth and shrink tumors in some people with cancer. Previous studies of combining durvalumab and chemotherapy showed that this combination is active in advanced mesothelioma. The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with MPM.
  • Adults (18 years or over) with a histological diagnosis of malignant pleural mesothelioma that is not amenable to curative surgical resection. Histological diagnosis requires tumour tissue from an open biopsy, or a core biopsy with a needle of 19 gauge or wider.

  • Measurable disease as per modified RECIST 1.1 (mRECIST 1.1) criteria for assessment of response in malignant pleural mesothelioma, without prior radiotherapy to these sites.

  • Body weight >30 kg,

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

  • Tumour tissue (Formalin-Fixed Paraffin-Embedded [FFPE]) available from diagnostic biopsy for PD-L1 testing and other correlative biomarker testing at a central laboratory.

  • Life expectancy of at least 12 weeks.

  • Adequate blood tests (done within 14 days prior to randomisation) and with values within the ranges specified below. Blood transfusions are permissible if completed at least 7 days prior to treatment start.

  • Haemoglobin ≥ 9.0 g/L

  • Absolute neutrophil count ≥ 1.5 x 10^9/L

  • Platelets ≥ 100 x 10^9/L

  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except participants with Gilbert's Syndrome, who are eligible with bilirubin ≤ 2.5 ULN)

  • Alanine transaminase ≤ 2.5 x upper limit of normal (ULN), unless liver metastases or invasion are present, in which case it must be ≤ 5 x ULN

  • Aspartate aminotransferase ≤ 2.5 x ULN, unless liver metastases or invasion are present, in which case it must be ≤ 5 x ULN

  • Creatinine clearance (CrCl) ≥ 45 mL/min (Cockcroft-Gault formula). NOTE: Carboplatin AUC 5 must be the initial platinum agent of choice in patients with creatinine Cl <60 mL/min but ≥ 45 mL/min, or those with clinically reported hearing loss.

  • Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient or legal representative must sign a consent form prior to enrolment in the trial to document their willingness to participate.

  • Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments.

  • Women of childbearing potential must use a reliable means of contraception during treatment and for at least 90 days thereafter. Breastfeeding is not permissible during or for at least 90 days after the final study treatment. Men must have been surgically sterilised or use a barrier method of contraception if they are sexually active with a woman of child bearing potential.

  • Evidence of post-menopausal status or negative serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.

  • Prior chemotherapy or other systemic anti-cancer or immunotherapy for MPM.

  • Diagnosis based only on cytology or aspiration biopsy with a needle narrower than 19 gauge.

  • Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g. colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion:

  • Patients with vitiligo or alopecia

  • Patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement

  • Any chronic skin condition that does not require systemic therapy

  • Patients without active disease in the last 5 years may be included

  • Patients with celiac disease controlled by diet alone

  • Any condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone or equivalent dose of an alternative corticosteroid) or other immunosuppressive medications within 28 days of durvalumab administration. Intranasal, inhaled or topical steroids or local steroid injections (e.g. intra-articular injection) are permitted in the absence of active autoimmune disease. Standard steroid premedication given prior to chemotherapy or as prophylaxis for imaging contrast allergy should not be counted for this criterion.

  • Participants with symptomatic or uncontrolled brain metastases or leptomeningeal disease are excluded.

  • Prior therapy with an anti-PD-1, anti-PD-L1 (including durvalumab), anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways.

  • Current treatment or treatment within the last 12 months with any investigational anti-cancer products.

  • Concurrent enrolment in another clinical study testing an anticancer treatment.

  • Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 msec in screening ECG measured using standard institutional method or history of familial long QT syndrome.

  • Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of study treatment on protocol. Note: Local surgery of isolated lesions for palliative intent is acceptable. Limited pleural biopsy procedures do not apply.

  • No other malignancy that requires active treatment. Participants with a past history of adequately treated carcinoma in situ, non-melanoma skin cancer or lentigo maligna without evidence of disease or superficial transitional cell carcinoma of the bladder are eligible.

  • Hearing loss or peripheral neuropathy considered by the investigators to contraindicate administration of either cisplatin, carboplatin or pemetrexed.

  • History of allergy or hypersensitivity to investigational product, cisplatin, carboplatin, pemetrexed or any excipient.

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive cardiac failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, active peptic ulcer disease or gastritis, serious chronic gastrointestinal conditions associated with diarrhoea, active bleeding diatheses.

  • Hepatitis B, hepatitis C or human immunodeficiency virus (HIV). Exceptions include past or resolved Hepatitis B (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) and patients positive for hepatitis C (HCV) antibody if polymerase chain reaction is negative for HCV RNA. HIV testing is not required in absence of clinical suspicion of HIV.

  • Known history of primary immunodeficiency, allogeneic organ transplant, pneumonitis or active tuberculosis.

  • Receipt of live attenuated vaccination within 30 days prior to enrolment or within 30 days of receiving durvalumab.

  • Specific comorbidities or conditions or concomitant medications which may interact with the investigational product(s).

  • Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.

  • Serious medical or psychiatric conditions or social situation that might limit compliance with study requirements, substantially increase risk of incurring adverse events or compromise the ability of the patient to give written informed consent.

United States
CA
San Diego
UC San Diego Medical Center - Hillcrest
Status: ACTIVE

CO
Aurora
University of Colorado Hospital
Status: WITHDRAWN
Contact: Lauren Dabdoub
Email: lauren.dabdoub@cuanschutz.edu

FL
Tampa
Moffitt Cancer Center
Status: ACTIVE

GA
Atlanta
Emory University Hospital / Winship Cancer Institute
Status: IN_REVIEW

IL
Chicago
University of Chicago Comprehensive Cancer Center
Status: ACTIVE

MA
Boston
Brigham and Women's Hospital
Status: ACTIVE

Dana-Farber Cancer Institute
Status: ACTIVE

Massachusetts General Hospital Cancer Center
Status: ACTIVE

MD
Baltimore
Johns Hopkins University / Sidney Kimmel Cancer Center
Status: ACTIVE

MI
Ann Arbor
University of Michigan Comprehensive Cancer Center
Status: ACTIVE

NJ
New Brunswick
Rutgers Cancer Institute of New Jersey
Status: ACTIVE

NY
New York
Memorial Sloan Kettering Cancer Center
Status: ACTIVE
Contact: Marjorie G. Zauderer
Email: zauderem@mskcc.org

OH
Cleveland
Case Comprehensive Cancer Center
Status: ACTIVE

Columbus
Ohio State University Comprehensive Cancer Center
Status: IN_REVIEW

PA
Philadelphia
Fox Chase Cancer Center
Status: ACTIVE
Contact: Ann Gorman
Email: ann.gorman@fccc.edu

University of Pennsylvania / Abramson Cancer Center
Status: ACTIVE

TN
Nashville
Vanderbilt University / Ingram Cancer Center
Status: ACTIVE

TX
Dallas
UT Southwestern / Simmons Cancer Center-Dallas
Status: ACTIVE

Houston
Baylor College of Medicine / Dan L Duncan Comprehensive Cancer Center
Status: ACTIVE

M D Anderson Cancer Center
Status: ACTIVE

Mesothelioma is a malignant tumor of the mesothelial surfaces primarily arising in the
      thoracic pleura. In the United Kingdom and USA the expected number of cases in the next few
      decades are 65,000 and 85,000, respectively. Once diagnosed, this disease is rarely cured
      with a median survival of less than a year.

      This is an International, Open-Label, Multi-center, Phase III study. Patients will be
      randomized 2:1 to receive durvalumab with standard chemotherapy or to receive standard
      chemotherapy alone.

      Arm A: Durvalumab every 3 weeks + standard chemotherapy (Cisplatin or Carboplatin every 3
      weeks + Pemetrexed every 3 weeks) for 4 to 6 cycles, followed by Durvalumab every 4 weeks.

      Arm B: Standard chemotherapy (Cisplatin or Carboplatin every 3 weeks + Pemetrexed every 3
      weeks) for 4 to 6 cycles followed by observation.

      Treatment with durvalumab in Arm A will continued until disease progression, unacceptable
      toxicity or patient withdrawal.

      Tumor assessments and Quality of Life forms will be performed at baseline, then at weeks 6,
      12, 18, 26, 34, 42, 50 and then every 12 weeks until disease progression.

      Mandatory pre-treatment tumor tissue sample (i.e., obtained during a previous procedure or
      biopsy) for research will also be required. Blood samples for research at baseline, day 1 of
      cycle 2, and day 1 of cycle 3 will be done.

      The study is being led jointly by PrECOG as the US sponsor and University of Sydney as the
      international sponsor

Interactive content above is from the official study record on the National Cancer Institute website, cancer.gov.



ECOG-ACRIN Cancer Research Group